Holen Sie sich die Stockscreener-App
337.05
0.27%
0.305
Schlusskurs vom Vortag:
$336.74
Offen:
$337.07
24-Stunden-Volumen:
7,424
Relative Volume:
0.01
Marktkapitalisierung:
$13.23B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
317.97
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
-0.58%
1M Leistung:
-0.18%
6M Leistung:
+22.16%
1J Leistung:
+28.71%
1-Tages-Spanne:
$337.00
$337.92
1-Wochen-Bereich:
$336.64
$340.71
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
337.20 | 13.21B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
110.19 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
357.80 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.08 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
70.05 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.53 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Risk Report: Is Penumbra Inc likely to announce a buybackBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Can Penumbra Inc. (0P8) stock sustain double digit ROEEntry Point & Daily Risk Controlled Trade Plans - Naître et grandir
Analyst Downgrade: Will Penumbra Inc. stock rally after Fed decisions2025 Dividend Review & Expert Curated Trade Ideas - Naître et grandir
Aug Shorts: What is the long term forecast for Penumbra Inc stock2025 Technical Patterns & Expert Approved Trade Ideas - baoquankhu1.vn
Picton Mahoney Asset Management Takes $1.03 Million Position in Penumbra, Inc. $PEN - MarketBeat
3 Reasons Boston Scientific Stock Could Quietly 5X as the World Ages - The Motley Fool
Blood Clot Retrieval Devices Market Size, Share & Forecast to 2036 - Fact.MR
Insider Sell: Maggie Yuen Sells Shares of Penumbra Inc (PEN) - GuruFocus
Insider Selling: Penumbra (NYSE:PEN) CFO Sells 2,432 Shares of Stock - MarketBeat
NZS Capital LLC Buys 17,355 Shares of Penumbra, Inc. $PEN - MarketBeat
Boston Scientific (NYSE: BSX) Explains Rationale for Penumbra Deal - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—THR, PEN, BCO, and ALGT - Carroll County Mirror-Democrat
Champlain Investment Partners LLC Trims Holdings in Penumbra, Inc. $PEN - MarketBeat
Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future - Sahm
Broker files Form 144 reporting PEN share sales (NYSE: PEN) - Stock Titan
(PEN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise - The Globe and Mail
Penumbra, Inc. (PEN) Stock Analysis: Unveiling the Potential in Medical Devices with a 4.57% Upside - DirectorsTalk Interviews
Citigroup Inc. Grows Stock Holdings in Penumbra, Inc. $PEN - MarketBeat
PEN shares climb after surpassing Q4 earnings and revenue expectations, with improved profit margins - Bitget
TD Asset Management Inc Sells 8,742 Shares of Penumbra, Inc. $PEN - MarketBeat
Artisan Partners Limited Partnership Raises Position in Penumbra, Inc. $PEN - MarketBeat
PEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Penumbra, Inc. $PEN Shares Acquired by Intech Investment Management LLC - MarketBeat
UBS Maintains Neutral on Penumbra (PEN) Feb 26, 2026 - Meyka
Penumbra (PEN) Earnings Surge Challenges Concerns Over Rich 75x P/E Valuation - simplywall.st
UBS reiterates Neutral on Penumbra stock, keeps $374 target By Investing.com - Investing.com Canada
Evercore ISI Maintains Outperform Rating and Raises PT for PEN t - GuruFocus
UBS reiterates Neutral on Penumbra stock, keeps $374 target - Investing.com
Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Decoding Penumbra Inc (PEN): A Strategic SWOT Insight - GuruFocus
Boston Scientific Still Navigating the Regulatory Process to Acquire Penumbra - Morningstar
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | BSX Stock News - Longbridge
Evercore ISI Maintained Outperform for Penumbra, Inc. (PEN) Feb 25, 2026 - Meyka
Evercore ISI raises Penumbra stock price target on embolization growth - Investing.com Nigeria
Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025 - Finviz
Evercore ISI raises Penumbra stock price target on embolization growth By Investing.com - Investing.com South Africa
Penumbra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financi - GuruFocus
Penumbra: Fourth Quarter Earnings Overview - Bitget
Penumbra (NYSE:PEN) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Penumbra Inc SEC 10-K Report - TradingView
Penumbra: Q4 Earnings Snapshot - marketscreener.com
Penumbra Q4 Non-GAAP Earnings, Revenue Rise - marketscreener.com
Penumbra Inc. (PEN) Releases Q4 2025 Earnings: Revenue and EPS Beat, Strong YoY Growth - Quiver Quantitative
Earnings Flash (PEN) Penumbra, Inc. Reports Q4 Revenue $385.4M, vs. FactSet Est of $361.9M - marketscreener.com
Earnings Flash (PEN) Penumbra, Inc. Posts Q4 Adjusted EPS $1.18 per Share, vs. FactSet Est of $1.11 - marketscreener.com
Penumbra Q4 Earnings Assessment - Benzinga
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):